Key Points
- Grigorios Siokas bought 113,185 shares on Jan. 12 at $0.50 ($56,592.50), bringing his direct holdings to 7,244,979 shares (~$3.62M); this purchase is one of several insider buys since November, signaling continued insider accumulation.
- Cosmos Health trades around $0.47 with a market cap of roughly $17.5M and a beta of 5.37, and it reported an EPS loss of ($0.17) that missed estimates; analysts expect a -0.78 EPS for the current year.
- Institutional interest is modest but rising—Citadel Advisors increased its stake to 225,507 shares (up 133%)—yet the average analyst rating remains Sell.
Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas bought 113,185 shares of the company's stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $0.50 per share, with a total value of $56,592.50. Following the completion of the acquisition, the chief executive officer directly owned 7,244,979 shares in the company, valued at $3,622,489.50. This trade represents a 1.59% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Grigorios Siokas also recently made the following trade(s):
- On Thursday, January 8th, Grigorios Siokas purchased 156,190 shares of Cosmos Health stock. The stock was bought at an average cost of $0.52 per share, for a total transaction of $81,218.80.
- On Wednesday, January 7th, Grigorios Siokas acquired 124,880 shares of Cosmos Health stock. The stock was bought at an average price of $0.52 per share, with a total value of $64,937.60.
- On Tuesday, January 6th, Grigorios Siokas bought 133,953 shares of Cosmos Health stock. The stock was purchased at an average price of $0.54 per share, for a total transaction of $72,334.62.
- On Friday, December 19th, Grigorios Siokas bought 88,314 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.49 per share, for a total transaction of $43,273.86.
- On Monday, December 15th, Grigorios Siokas purchased 168,472 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.42 per share, with a total value of $70,758.24.
- On Friday, November 28th, Grigorios Siokas purchased 76,360 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.64 per share, for a total transaction of $48,870.40.
- On Tuesday, November 25th, Grigorios Siokas acquired 55,732 shares of Cosmos Health stock. The stock was purchased at an average price of $0.63 per share, for a total transaction of $35,111.16.
- On Friday, November 21st, Grigorios Siokas acquired 56,080 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.68 per share, with a total value of $38,134.40.
- On Thursday, November 20th, Grigorios Siokas bought 51,315 shares of Cosmos Health stock. The shares were purchased at an average price of $0.62 per share, with a total value of $31,815.30.
- On Wednesday, November 19th, Grigorios Siokas bought 61,614 shares of Cosmos Health stock. The stock was acquired at an average cost of $0.65 per share, for a total transaction of $40,049.10.
Cosmos Health Stock Down 7.1%
Shares of NASDAQ:COSM opened at $0.47 on Wednesday. Cosmos Health Inc. has a 1 year low of $0.28 and a 1 year high of $1.32. The company has a market cap of $17.50 million, a PE ratio of -0.62 and a beta of 5.37. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84. The stock's 50-day moving average is $0.57 and its 200 day moving average is $0.73.
Cosmos Health (NASDAQ:COSM - Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.16). Cosmos Health had a negative return on equity of 33.19% and a negative net margin of 31.01%.The business had revenue of $17.11 million during the quarter, compared to analysts' expectations of $16.40 million. Sell-side analysts anticipate that Cosmos Health Inc. will post -0.78 EPS for the current year.
Hedge Funds Weigh In On Cosmos Health
A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC raised its position in shares of Cosmos Health Inc. (NASDAQ:COSM - Free Report) by 133.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 225,507 shares of the company's stock after buying an additional 128,776 shares during the quarter. Citadel Advisors LLC owned about 0.65% of Cosmos Health worth $250,000 at the end of the most recent quarter. 12.61% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of brokerages have issued reports on COSM. Weiss Ratings reissued a "sell (d-)" rating on shares of Cosmos Health in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Cosmos Health to a "hold" rating in a research note on Saturday, September 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of "Sell".
Check Out Our Latest Stock Report on Cosmos Health
About Cosmos Health
(
Get Free Report)
Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
